This website is intended for healthcare professionals only.

Hospital Healthcare Europe
Hospital Pharmacy Europe     Newsletter       

Press Releases

Take a look at a selection of our recent media coverage:

Unlocking the female bias in lupus

8th April 2019

Eighty-five percent of people with lupus are female, and their second X chromosome seems partly to blame. 
 
According to a new study by researchers at the University of Pennsylvania, females with lupus do not fully “silence” their second X chromosome in the immune system’s T cells, leading to abnormal expression of genes linked to that chromosome.
 
The work, led by Montserrat Anguera of the School of Veterinary Medicine and published in the journal JCI Insight, is the first to connect disruptions in maintaining X chromosome inactivation in T cells to lupus. It also suggests that changes to the nuclear structure in the inactive X chromosome of T cells may play a part in the genetic missteps that can arise in lupus – the first time that nuclear organisation has been noted as a feature of this disease.
 
In normal circumstances, the inactive X should be silenced, and what we show is, in lupus, it’s not,” says Anguera, a biologist at Penn Vet. “And it’s ultimately affecting gene expression.”
 
Anguera’s lab has paid close attention to the link between X chromosome inactivation, an epigenetic process that balances gene expression between males and females, and autoimmune disease. In earlier studies, the team found that, in females, both T cells and B cells have incomplete inactivation of the second X chromosome due to changes in the patterns of Xist, an RNA molecule that is necessary for X inactivation.
 
The researchers used a mouse model that spontaneously develops lupus in a female-biased manner, similar to the human disease. All female mice of this strain develop the disease, while only 40% of males do. Examining the animals’ T cells, the researchers discovered that those at early stages of disease resembled healthy controls in their patterns of Xist localisation. But those in the later stages of disease had a dramatically different pattern.
 
The only differences we detected happened at late stages of disease,” Anguera says. “What this means is that abnormal X inactivation is a consequence of the disease; it’s not predisposing the animal to develop the disease.”
 
Interestingly, when the researchers looked at T cells from paediatric lupus patients,  they found the same mislocalisation of Xist that they had seen in the mice with lupus, even though the children were in remission from their disease.
 
Even stimulating those patients’ cells in vitro wasn’t enough to coax Xist into the normal pattern. “Even though they don’t have active disease, there’s something missing that’s preventing the RNA from staying targeted at that inactive X chromosome,” Anguera says.
 
What we think is happening is that in lupus, this Xist RNA is diffusing all over the place, these chromosomal proteins are changing their expression, and nuclear organisation in the territory of the inactive X is changing,” Anguera says. “And that may also be contributing to the relaxed silencing of the inactive X and the changes in gene expression that we’re seeing.”
 
In the future, the researchers plan to use single-cell sequencing technology to probe questions about the maintenance and disruption of X inactivation. And though the research is in early days, Anguera is hopeful that further work will lead to new approaches for treating autoimmune diseases such as lupus.

Warnings over fluoroquinolone antibiotics after reports of ‘irreversible’ side effects

5th April 2019

The UK medicines watchdog has issued guidance on fluoroquinolone antibiotics following some reports of ‘potentially irreversible’ side effects affecting multiple systems, organ classes and senses.

The Medicines and Healthcare Regulatory Authority (MHRA) cautioned healthcare professionals on 21 March against prescribing the drug and to advise patients to stop taking it if they experienced side effects including muscle pain and peripheral neuropathy.

This is part of new restricted indications following an EU-wide safety review of the drug following ‘relatively few’ reports of serious side effects usually affecting the musculoskeletal and nervous systems. It is likely that the number of those adversely affected by the drug has been under-reported, the MHRA said.

Taking fluoroquinolone – which is prescribed for serious, life-threatening bacterial infections – by mouth, injections or inhalation can ‘very rarely’ cause these side effects for up to months or years, according to the MHRA.

It should not be prescribed for mild to moderate infections unless other antibiotics are considered inappropriate.

Some of the serious side effects reported include tendon rupture, depression, fatigue, memory impairment and arthralgia.

2019 update of the EULAR recommendations for the management of SLE

EULAR has published an update to a set of recommendations for the management of systemic lupus erythematosus (SLE). 
Treatment in SLE aims at remission or low disease activity and prevention of flares. The updated recommendations provide physicians and patients with updated consensus guidance on the management of SLE.
A systematic literature review was performed, followed by the modified Delphi method, which was used to form questions, elicit expert opinions and reach consensus. The methods / methodological approach included pharmacologic treatment of SLE; management of specific manifestations; monitoring SLE and treatment targets; comorbidities and adjunct therapy.
Based on the evidence and expert opinion from an international task force, overarching principles and recommendations were formulated. Four overarching principles and 13 recommendations were agreed upon. The four overarching principles are:
  • SLE is a multisystem disease – occasionally limited to one or few organs – diagnosed on clinical grounds in the presence of characteristic serologic abnormalities.
  • SLE care is multidisciplinary, based on a shared patient-physician decision, and should consider individual, medical and societal costs.
  • Treatment of organ-/life-threatening SLE includes an initial period of high-intensity immunosuppressive therapy to control disease activity, followed by a longer period of less intensive therapy to consolidate response and prevent relapses.
  • Treatment goals include long-term patient survival, prevention of organ damage and optimisation of health-related quality of life.
The recommendations are categorised into four parts:
  1. Goals of treatment
  2. Treatment of SLE (general)
  3. Specific manifestations
  4. Comorbidities.
The summary of recommendations in lay format are:
  1. The goal of treatment in lupus is to control activity of the disease and prevent flares
  2. All patients with SLE should receive hydroxychloroquine, with regular monitoring for eye toxicity
  3. Glucocorticoids (GC, cortisone) can help to control symptoms when the disease is active. In the long-term its dose must not exceed 7.5 mg/day of prednisone
  4. Immunosuppressive drugs such as methotrexate, azathioprine and mycophenolate can be used to better control the disease and allow using less glucocorticoids
  5. When lupus cannot be controlled with the conventional drugs, biologic drugs like belimumab or rituximab can be used
  6. Skin disease in lupus is initially treated with creams/ointments or hydroxychloroquine, with or without oral glucocorticoids. When these do not control the disease, immunosuppressives or biologics can be used
  7. Symptoms involving the brain and nervous system are not always due to lupus. When caused by lupus, immunosuppressive drugs or aspirin/anticoagulants are used
  8. Severe drops in platelets or low blood counts from SLE are treated with GC and immunosuppressive drugs; in case of relapses, rituximab should be considered
  9. Biospy of the kidney is essential to diagnose kidney involvement in lupus.Immunosuppressive drugs of first-choice are mycophenolate mofetil and cyclophosphamide
  10. A second kidney biopsy may be considered in cases of incomplete response after one year of treatment
  11. Patients with lupus should be tested for antiphospholipid antibodies, because the latter are associated with blood clots (thrombosis), pregnancy loses s and other complications such as strokes.
  12. Patients with SLE have an increased risk for infections and should be vaccinated against influenza and pneumococcus, as well as human papilloma virus (adolescents)
  13. Patients with SLE may suffer more from heart attacks and strokes. To decrease the risk for these complications, quitting smoking, and control of high blood pressure, dyslipidaemia, diabetes are essential.
The level of evidence, grade of recommendation and level of agreement were allocated to each statement.

Bronchiectasis associated with high frequency of allergy

An international research team from Singapore has found that patients with the lung disease bronchiectasis also often display sensitivity to airborne allergens, and has highlighted the particular role that fungi appear to play.
 
Their discovery suggests that bronchiectasis patients should be examined for a range of allergies, since the treatment for allergies already exists and controlling them could prevent the bronchiectasis from worsening.
 
Bronchiectasis is a chronic disease in which parts of the airways have enlarged, due to irreversible damage to the lungs. Patients find it hard to cough out phlegm and are more prone to bacterial, viral or fungal infection. These complications can be fatal if left untreated, and the disease itself has no effective cure.
 
Led by Assistant Professor Sanjay Haresh Chotirmall from the Lee Kong Chian School of Medicine (LKCMedicine) at NTU, the team included researchers from Tan Tock Seng Hospital, Singapore General Hospital, Changi General Hospital, National University of Singapore, Agency for Science, Technology and Research (A*STAR), National University of Malaysia, and the University of Dundee in Scotland. Their findings have been published in the American Journal of Respiratory and Critical Care Medicine.1
 
They assessed fungal infection in over 200 bronchiectasis patients from Singapore, Malaysia and Scotland. While previous bronchiectasis research focused on non-Asian populations, this new study matched patients in Asia (Singapore and Malaysia) to patients in Europe (Scotland) in terms of age, gender and the severity of bronchiectasis.
 
The matching of patients allowed researchers to control the influence of these factors and hence show that the types and causes of allergies associated with bronchiectasis vary across regions.
 
They found that overall, bronchiectasis patients have high allergy rates to fungi and the common house dust mite. The study showed that 58% of bronchiectasis patients were sensitive to at least one allergen, compared to a group of patients with allergic rhinitis where 27% were sensitive.
 
Asst Prof Chotirmall, NTU Provost’s Chair in Molecular Medicine, said, “We have found that bronchiectasis is often associated with allergic reactions to fungi and to the house dust mite. There are already existing treatments for these allergies, for example, steroids are commonly used to treat fungal allergy. Our finding is important for improving the quality of life of those with bronchiectasis, as currently there are no licensed treatments for it.”
 
Reference
  1. Aogáin M et al. Distinct “Immunoallertypes” of disease and high frequencies of sensitization in non-cystic fibrosis bronchiectasis. Am J Resp Crit Care Med 2019;199(7):842.

New treatment combination available first-line to treat advanced kidney cancer

Bristol-Myers Squibb has announced that the National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Determination (FAD) recommending the combination of Opdivo® (nivolumab) plus Yervoy® (ipilimumab) to treat NHS patients in England with renal cell carcinoma (RCC). 
 
This recommendation signifies an important landmark in the treatment landscape representing the first approval of an immuno-oncology combination therapy for first-line patients with this type of cancer in England. Nivolumab and ipilimumab will be immediately available on the Cancer Drugs Fund as a first-line treatment option for previously-untreated intermediate- and poor-prognostic risk advanced RCC, and could be a treatment option for up to 1700 patients each year in England. 
 
Today’s decision is of importance to advanced kidney cancer patients, who may now have access to more treatment options,” said Rose Woodward, Co-founder of the Kidney Cancer Support Network. “Kidney cancer is a devastating disease and at the most advanced stage prognosis is poor. Having access to this combination therapy on the NHS is therefore an important new addition and a vital step in our fight to extend survival.”
 
The recommendation is based on data from the Phase III CheckMate 214 study of 1096 patients, which was stopped early after a planned interim analysis showed that the combination of nivolumab and ipilimumab demonstrated superior overall survival compared to sunitinib, a current standard of care.
 
It’s very good news that the combination of nivolumab and ipilimumab has now been approved for use in patients with intermediate- and poor risk advanced renal cell carcinoma. A study has demonstrated that this immunotherapy combination is superior to sunitinib in extending overall survival and may now benefit patients whose lives are threatened by a cancer that has increased in incidence by nearly 50% in the last decade,” said Dr Paul Nathan, Consultant Medical Oncologist at Mount Vernon Cancer Centre, East and North Hertfordshire NHS Trust.
 
We are delighted that NICE has recognised the combination of nivolumab plus ipilimumab as an important treatment option for many patients with advanced RCC. Importantly, the decision may allow intermediate- and poor risk patients in England to receive immunotherapy as a first-line option for the first time,” said Lynelle Hoch, General Manager, Bristol-Myers Squibb UK & Ireland. “Today’s recommendation helps to further our goal of ensuring that increasing numbers of patients will be able to benefit from potentially life-extending medicines.C
 
ancer Research UK. Kidney Cancer. Types and Grades. Available at:
 
https://www.cancerresearchuk.org/about
-cancer/kidney
-cancer/stages
-types
grades/types
-grades
. Last accessed April
2019.
2
National Institute for Health and Care Excellence. NICE Pathways: Renal cancer overview. Available at:
https://pathways.nice.org.uk/pathways/renal
-cancer/renal
-cancer
-overview#content=view
-node:nodes
-first
-line
-treatment
-for
-advanced
-and
metastatic
-renal
-cancer
. Last accessed April
2019.
3
National Institute for Health and Care Ex
cellence. Nivolumab with ipilimumab for untreated metastatic renal cell carcinoma [ID1182].
https://www.nice.org.uk/guidance/indevelopment/gid
-ta10189/documents
. Last acce
ssed April 2019.
Cancer Research UK. Kidney Cancer. Types and Grades. Available at:
https://www.cancerresearchuk.org/about
-cancer/kidney
-cancer/stages
-types
grades/types
-grades
. Last accessed April
2019.
2
National Institute for Health and Care Excellence. NICE Pathways: Renal cancer overview. Available at:
https://pathways.nice.org.uk/pathways/renal
-cancer/renal
-cancer
-overview#content=view
-node:nodes
-first
-line
-treatment
-for
-advanced
-and
metastatic
-renal
-cancer
. Last accessed April
2019.
3
National Institute for Health and Care Ex
cellence. Nivolumab with ipilimumab for untreated metastatic renal cell carcinoma [ID1182].
https://www.nice.org.uk/guidance/indevelopment/gid
-ta10189/documents
. Last acce
ssed April 2019.
Cancer Research UK. Kidney Cancer. Types and Grades. Available at:
https://www.cancerresearchuk.org/about
-cancer/kidney
-cancer/stages
-types
grades/types
-grades
. Last accessed April
2019.
2
National Institute for Health and Care Excellence. NICE Pathways: Renal cancer overview. Available at:
https://pathways.nice.org.uk/pathways/renal
-cancer/renal
-cancer
-overview#content=view
-node:nodes
-first
-line
-treatment
-for
-advanced
-and
metastatic
-renal
-cancer
. Last accessed April
2019.
3
National Institute for Health and Care Ex
cellence. Nivolumab with ipilimumab for untreated metastatic renal cell carcinoma [ID1182].
https://www.nice.org.uk/guidance/indevelopment/gid
-ta10189/documents
. Last acce
ssed April 2019.

Expert analysis: Transition from childhood to adult care in coeliac disease

4th April 2019

Transition is defined as the purposeful, planned movement of adolescents and young adults from a child-centred to adult-oriented health care system.1
 
It represents a delicate moment for the patient and the family, who are both at the centre of the transition, and a challenge for the physician, who guides and coordinates this process. In fact, in children, the delivery of care is fundamentally family-centred, whereas in adults, responsibility becomes autonomous. This means that adolescents have to work hard to overcome their reliance on parents and, on the other hand, parents might find it difficult to step back and alow adolescents to make independent decisions.2 In this process, both overprotection and inadequate support might be detrimental and could lead to an unsuccessful transition, with increased complications and low quality of life in adulthood.
 
Transition is nowadays an emerging and important issue because the number of children affected by chronic diseases or complex disabilities is increasing. In the US, approximately 20% of adolescents have special health care needs and it is estimated that less then 50% of patients aged 12–17 years receive adequate support and services for their transition to adult care.3 Lower numbers still are registered in ethnic minorities and poorer sections of the population. The low rates of transition support may be related to the fact that only 30% of paediatricians make referrals to adult physicians, and only 15% provide transition education materials.4
 
The transition process
Although the age of transition to adult care might vary, according to differing growth and maturation among individuals, it is suggested that discussion of transition plans should be introduced early, ideally between 12 and 14 years and the plans should be developed between 14 and 16 years of age. Transfer should take place around 18 years of age, always considering the grade of maturation and the patients will. Moreover, transition can be triggered by important events in the patient’s life: for example, age, leaving school, marriage, pregnancy, etc. It should be emphasised that transition to an adult provider is a complex process, not just one event (Figure 1).
 
Figure 1: The transition process
Figure 1: Click image to view larger version
 
During transition, several factors that could prohibit a successful outcome should be considered and prevented. The barriers could be related to the patient themselves (emotional or cognitive delay, immaturity, difficulties in communication with health provider5 and, above all, attachment to paediatric institution and non-compliance with transfer6,7), to the family (parents’ anxiety and concerns, difficulties in communication with the adolescent, excessive attachment to paediatric health care providers), or to other factors (health insurance issues). 
 
Transition can follow many models. In some settings, paediatric and adult medical teams meet the patient at the same visit to discuss transition; in others, both paediatric and adult clinicians meet annually to prepare transfer. Joint transition clinics with paediatric and adult clinician should be established in order to allow a smooth transfer of the patient, generating trust in the new physician. This models have been linked to good outcomes such as improved care and better health-related quality of life (QoL).8
 
Focus on coeliac disease: specific aspects
While there are several transition recommendations for chronic disease, very few documents have been written about transition in coeliac disease (CD).2 The fact that there is no need for specific drugs, and often there are no symptoms from not adherence to gluten-free diet (GFD), makes CD perceived as a not severe disease by adolescents and adult gastroenterologists and creates specific barriers for transition in this category of patients. This calls for a ‘transition document’, created by the paediatrician and containing essential data about diagnosis, growth, follow up, comorbidities, psychological aspects and dietary compliance.  This document allows a more structured and efficient transition process.
 
According to ESPGHAN/NASPGHAN criteria, routine small intestinal biopsy is not recommended to reconfirm the diagnosis of paediatric CD patients. This differs from adult policy, because in adult care is a follow-up biopsy is frequently required to document healing for future management and prognostic information. Nevertheless, there are specific situations which require to repeat biopsy before the transition: if CD diagnostic criteria have not been fulfilled at the moment of the diagnosis, if symptoms suggest active CD or other diagnosis, if patient or clinician necessitates documentation of histological healing, if the adolescent is not following gluten free diet. A gluten challenge after transition is normally not required if diagnostic criteria have been followed, also in children younger than two years.9 A gluten challenge, traditionally made for three months and with an adequate amount of gluten, should be considered when the primary diagnosis of CD has not met standards and guidelines, or when patient requests proof of the diagnosis. There are not clear guidelines in gluten challenge. Nevertheless, it is recommended to perform specific CD serology and biopsy before the challenge and to monitor it with serology. An increase in CD-serum autoantibodies, also without relapse of symptoms, is related to deterioration of histology and suggests to perform the biopsy.
 
Many issues should be discussed with the patient when approaching transition: medical monitoring schedule with lab tests and visits, risk of complications (even if the patient remains asymptomatic) sexual and fertility problems,10 implications with future career, psychological problems and, above all, GFD adherence, strategies and complications in case of poor compliance. Decrease in compliance has been reported among adolescents in several studies.11 It is estimated that up to 40%12 of adolescents fail to adhere to GFD and the main reason is that they believe that a systematic low intake of gluten does not affect their health, as it does not cause any intestinal symptoms.13 This lack of information is extremely dangerous and lead to poor outcome in adult healthcare. This calls for new communication strategies in order to overcome differences in culture and language between the adolescent and his physician. Flexibility in communication styles should be implemented. In this scenario, technology (videoconferences, SMS messages,14 online consultations, emails,15 apps) may improve adherence to therapy, allow earlier identification of medical deterioration represents an important aid for continuous education.
 
Conclusions
This brief article highlights the complexity of transition process and underlines the necessity of transition policies. This calls for development of clear specific guidelines based on outcome-related research. Different models should be evaluated in RCTs to overcome specific transition items such as barriers to successful outcomes, poor compliance and complications, in order to improve quality of life for the future adult. 
 
References
  1. Blum RW et al. Transition from child-centered to adult health-care systems for adolescents with chronic conditions. A position paper of the Society for Adolescent Medicine. J Adolescent Health 1993;14:570–6.
  2. Ludvigsson JF et al. Transition from childhood to adulthood in coeliac disease: the Prague consensus report. Gut 2016;65:1242–51. 
  3. McManus MA et al. Current status of transition preparation among youth with special needs in the United States. Pediatrics 2013;131:1090–7.
  4. Davis AM et al. Transition care for children with special health care need.s Pediatrics 2014;134;900. 
  5. Bryon M, Madge S. Transition from paediatric to adult care: psychological principles. J R Soc Med 2001;94(suppl 40):5–7
  6. Reiss JG, Gibson RW, Walker LR. Health care transition: youth, family, and provider perspectives. Pediatrics 2005;115:112–20.
  7. Kyngas H, Hentinen M, Barlow JH. Adolescents’ perceptions of physicians, nurses, parents and friends: help or hindrance in compliance with diabetes self-care? J Adv Nurs 1998;27:760–9
  8. Crowley R, Wolfe I, Lock K, et al. Improving the transition between paediatric and adult healthcare: a systematic review. Arch Dis Child 2011;96:548–53.
  9. Husby S et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr 2012;54:136–60.
  10. Zugna D et al. A nationwide population-based study to determine whether coeliac disease is associated with infertility. Gut 2010;59:1471–5.
  11. Errichiello S et al. Celiac disease: Predictors of compliance with a gluten-free diet in adolescents and young adults. JPGN 2010;50:54–60.
  12. Czaja-Bulsa G, Bulsa M. Adherence to gluten-free diet in children with celiac disease. Nutrients 2018;10:1424.
  13. Freeman HJ. Dietary compliance in celiac disease. World J Gastroenterol 2017;23(15):2635–9.
  14. Haas K, Martin A, Park KT. Text message intervention (TEACH) improves quality of life and patient activation in celiac disease: A randomized clinical trial. J Pediatr 2017;S0022-3476:30328-1.
  15. Harvey K et al. Health communication and adolescents: what do their emails tell us? Fam Pract 2008;25:304–11.

Expert view: Refining the use of belimumab in patients with SLE

2nd April 2019

The treatment of systemic lupus erythematosus (SLE) has traditionally been non-specific, comprising glucocorticoids, non-steroidal anti-inflammatory drugs and broad immunosuppressive agents.
 
The monoclonal antibody belimumab towards the soluble counterpart of the B cell activating factor belonging to the tumour necrosis factor family (BAFF), also known as B lymphocyte stimulator (BLyS), is the only targeted therapy approved by regulatory agencies for SLE, and has been available for use since 2011.1
 
An early post-hoc analysis of the pivotal Phase III clinical trials of belimumab, that is, BLISS-52,2 and BLISS-76,3 showed superiority of belimumab over placebo in SLE patients with high baseline disease activity, positive anti-double stranded (ds)DNA titres and low complement levels, as well as in patients receiving corticosteroids.4 Later, real-life observations demonstrated that established organ damage prior to treatment initiation predicted reduced belimumab efficacy based on the SLE Responder Index 4 (SRI-4),5 which was recently corroborated in a post-hoc analysis of data from the BLISS-52 and BLISS-76 trials.6 Interestingly, in the latter analysis the investigators found no association between response to belimumab treatment and anti-dsDNA positivity or hypocomplementaemia in the belimumab 10mg/kg arm, and low C3/C4 levels even predicted non-response in the belimumab 1mg/kg and placebo arms. Even though the results from the two studies are not contradictory, the conclusions drawn could have different impacts on the use of belimumab treatment. The first analysis4 was of comparative nature, with the purpose of revealing differences between belimumab and placebo, whereas the recently published post-hoc analysis6 studied predictors of response in the different trial arms separately. Practically, the results from the latter study suggest that this relatively new biologic agent can also be efficacious in SLE patients with no current serologic activity, contributing to refinement of the recommendations of its use. 
 
The observed association between established organ damage and reduced drug efficacy was further disseminated to the separate organ systems; interestingly, in both studies, thrombotic events were found to mainly account for the association, raising the question of whether the antiphospholipid antibodies (aPL) or syndrome (APS), a severe coagulopathy commonly seen in SLE patients, or treatment with anticoagulants as a result of this diagnosis, could be an underlying mechanistic explanation. Further survey on this is awaited. 
 
The SLE populations of the pivotal BLISS-52 and BLISS-76 trials constitute large patient cohorts, ideal for post-hoc survey to better understand the disease itself, and the effects of belimumab treatment. When conducting a clinical trial, the main aim is to show differences between the active substance and placebo in its ability to reduce disease activity. At a later stage, it is important to scrutinise the data in order to better understand the clinical and immunological effects of the approved dose of the drug over time, as well as factors that might contribute to its efficacy or inefficacy, aiming at optimising its use. Interpretation of results derived from clinical trial data has to take into account the purpose of the study settings, in order to ensure the most advantageous guidance possible in decision making.  
 
References
  1. Parodis I, Axelsson M, Gunnarsson I. Belimumab for systemic lupus erythematosus: a practice-based view. Lupus 2013;22(4):372–80. 
  2. Navarra SV et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377(9767):721–31. 
  3. Furie R et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63(12):3918–30. 
  4. van Vollenhoven RF et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis 2012;71(8):1343–9. 
  5. Parodis I et al. Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus. Autoimmun Rev 2017;16(4):343–51. 
  6. Parodis I et al. Established organ damage reduces belimumab efficacy in systemic lupus erythematosus. Ann Rheum Dis 2019;Epub 2019/01/06:doi: 10.1136/annrheumdis-2018-214880.

Protecting against heart disease in lupus and beyond

28th March 2019

 
A research team at the Medical University of South Carolina (MUSC) has shown that the enzyme responsible for nitric oxide production stops working properly when exposed to serum from lupus patients. They also showed that its ability to produce nitric oxide can be restored by administration of L-sepiapterin. Their findings are published in an article published ahead of print in Lupus Science & Medicine.1
 
The article provides proof of concept that the enzyme could be a therapeutic target for heart disease in lupus. Restoring the enzyme’s function could also help protect lupus patients against kidney disease. The same inflammatory forces are at work there but the damage occurs much more quickly.
 
The findings also suggest that restoring the protective function of endothelial cells could be a strategy for treating heart disease more broadly.
 
“Our study demonstrates that therapies directed towards restoring the function of the enzyme that makes nitric oxide might be effective in restoring the function of the endothelium,” explains Jim C Oates, MD, senior author on the article and Director of the Division of Rheumatology & Immunology and vice chair for research at MUSC.
 
“So it’s a proof of concept that allows us to move forward in studying the enzyme, nitric oxide synthase, or restoring its function as a target for vascular disease in lupus,” continues Oates.
 
“This is a first step in a long process of trying to identify therapeutics that might be useful for preventing this accelerated phenotype of cardiovascular disease in lupus patients,” says Joy Buie, PhD. MSCR, a postdoctoral fellow at MUSC and the first author on the article.
 
For the study, the team collected serum samples from a cohort of African American patients, specifically Gullah patients, with lupus who have been followed since 2003. The South Carolina Clinical & Translational Research Institute at MUSC helped the research team collect study samples from control volunteers, process study samples from both study patients and control volunteers, and securely store collected data.
 
The MUSC team showed that exposing endothelial cells to serum from patients with lupus caused endothelial nitric oxide synthase to stop working properly. Instead of producing the protective nitric oxide, it began producing superoxide, which promoted damaging inflammation.
 
In essence, the enzyme lost its power to protect against heart disease and instead promoted conditions that could lead to it. A co-factor needed for the proper function of the enzyme had been rendered unusable by exposure of the endothelial cells to the serum of lupus patients.
 
Administering L-sepiapterin to the cells restored the enzyme’s ability to produce nitric oxide by providing a new and more reliable source of that co-factor.
 
Reference
  1. Jones Buie JN et al. L-sepiapterin restores SLE serum-induced markers of endothelial function in endothelial cells. Lupus Sci Med 2019;6(1):e000294 DOI: 10.1136/lupus-2018-000294

Cancer Research UK, LifeArc and Ono Pharma form cancer therapy alliance

A multi-year partnership brings together Cancer Research UK’s network of world-leading scientists and drug discovery expertise, LifeArc’s renowned therapeutic antibody engineering and development expertise, and Ono’s considerable track record in developing cancer immunotherapies.
 
The collaboration will identify targets for the development of both antibody and small molecule therapeutics. Boosted by a multimillion pound investment from Ono and a further investment from LifeArc, drug discovery experts will be pursuing targets within Cancer Research UK’s extensive portfolio of immuno-oncology research.
 
This new collaboration expands upon an existing alliance between Cancer Research UK and LifeArc announced in 2017. Ono’s investment and expertise will help identify new therapeutic targets, accelerate target validation within the alliance, and support validated targets through the drug discovery phase.
 
Dr Hamish Ryder, director of Cancer Research UK’s Therapeutic Discovery Labs, said: “We’re thrilled to welcome Ono to join and expand our successful collaboration with LifeArc and create one of our most ambitious alliances to date. This unique alliance is a melting pot of world-leading cancer research and each organisation’s extensive expertise in oncology drug discovery.”
 
As we enter into a new age of immuno-therapeutic approaches to cancer care, we hope that this partnership will accelerate the development of new treatments, bringing them to patients with cancer much faster.”
 
Under the terms of the deal, LifeArc will progress antibody projects via its antibody screening and development expertise. Small molecule projects will be taken forward by Cancer Research UK’s Therapeutic Discovery Labs.

European Phase III trial of peanut allergy drug meets primary endpoint

Aimmune has announced that its Phase III European clinical trial of AR101 for the treatment of peanut allergy, known as ARTEMIS (AR101 Trial in Europe Measuring oral Immunotherapy Success), met its primary efficacy endpoint. 
 
Topline data show that the proportion of AR101-treated patients who tolerated a 1000-mg dose of peanut protein (2043mg cumulative) in a blinded exit challenge after approximately nine months of AR101 treatment was significantly higher (p<0.00001) than in the placebo group. Specifically, the median tolerated dose of peanut protein for AR101-treated patients improved 100-fold, from 10mg at baseline to 1000mg at exit. The trial also greatly exceeded a 15% lower-bound of the 95% confidence interval (CI) of the difference between treatment arms for all endpoints.
 
In addition, the safety profile and completion rate observed in ARTEMIS are consistent with the results seen in previous AR101 clinical trials. Notably, no cases of anaphylaxis or of eosinophilic esophagitis were observed. Aimmune plans to present full results in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress in early June.
 
The ARTEMIS findings reinforce the results from the highest level tested in Aimmune’s landmark Phase III PALISADE trial, which found that 50.3% of AR101-treated patients tolerated a single highest dose of 1000mg of peanut protein (2043mg cumulative) after approximately six months of dose escalation followed by six months at a daily therapeutic dose of 300mg, compared to 2.4% of placebo patients (p<0.00001). Full results from the PALISADE trial were published in November 2018 in the New England Journal of Medicine.
 
ARTEMIS enrolled 175 children and adolescents ages 4 to 17 from 18 sites in France, Germany, Ireland, Italy, Spain, Sweden and the UK. Patients underwent approximately six months of dose escalation and then three months at a daily therapeutic dose of AR101 at 300 mg or placebo, followed by an exit double-blind, placebo-controlled food challenge. The primary efficacy endpoint was patients’ ability to tolerate a 1000-mg single dose of peanut protein, the equivalent of approximately three to four peanut kernels (2043mg cumulative, equivalent to seven or eight peanut kernels).
 
Based on these positive results, Aimmune intends to submit a marketing authorisation application for AR101 to the European Medicines Agency in mid-2019.

x